IGF-1 LR3 (Long R3 IGF-1): The Complete Research Guide

What is IGF-1 LR3 (Long R3 IGF-1)?

IGF-1 LR3, also written Long R3 IGF-1, is an engineered analog of human insulin-like growth factor 1 (IGF-1) — a naturally occurring polypeptide hormone that mediates many of the growth-promoting effects of growth hormone. The analog differs from native IGF-1 in two ways: an arginine (R) substitution at position 3 and a 13-amino-acid N-terminal extension (the "Long" prefix). Together these modifications dramatically reduce the molecule's affinity for IGF-binding proteins (IGFBPs).

Because native IGF-1 circulates largely bound to IGFBPs, the free, active fraction is tightly regulated. By resisting those binding proteins, IGF-1 LR3 has been studied as a longer-acting, more readily available form of IGF-1 in model systems — which is also why the analog is a common cell-culture supplement in research and bioprocessing. Throughout this guide the compound is discussed strictly as a research material — it is intended exclusively for laboratory use and is not a medicine.

What the research explores

In laboratory settings, IGF-1 and its analogs have most often been studied across a handful of interconnected areas:

• Cell proliferation — IGF-1 and LR3-IGF-1 have been used to study replication in cultured cell populations, including comparisons of their dose-response behavior.
• Skeletal-muscle biology — research has examined IGF-1 signaling in muscle protein synthesis, hypertrophy, and atrophy pathways.
• Muscle regeneration — IGF-1 isoforms and satellite (stem) cell activation have been studied in tissue-repair models.
• Growth-signaling pathways — the IGF-1 receptor and its downstream PI3K/Akt cascade are examined as candidate mechanisms.

Purity, testing, and certificates of analysis

In research, the reliability of a result depends on the identity and purity of the material behind it. Every batch of IGF-1 LR3 from Peptora is HPLC-verified to 99%+ purity, confirmed by LC-MS identity testing, and screened across a full quality-control panel before release. Each order ships with a lot-specific certificate of analysis (COA) so the material can be matched to its documentation.

Researchers often choose Peptora precisely because this documentation is standard rather than optional. To understand what each figure on a report means, see the guide on the certificate of analysis.

Handling IGF-1 LR3 in the laboratory

IGF-1 LR3 is supplied as a lyophilized (freeze-dried) powder. Before research use it is reconstituted with bacteriostatic water, which is sold separately. As a larger polypeptide, IGF-1 LR3 is particularly sensitive to handling, so gentle technique matters:

1. 1Allow the sealed vial to reach room temperature before opening.
2. 2Add bacteriostatic water slowly against the vial wall; swirl gently and do not shake or vortex.
3. 3Let the powder dissolve fully before drawing.
4. 4Store the reconstituted solution refrigerated and protected from light.

Full step-by-step protocols live in the reconstitution guide. Following them consistently is one of the simplest ways to keep research reproducible.

Scientific references

IGF-1 and the Long R3 analog have been studied across cell-culture, animal, and human physiological research over several decades. The literature below is provided for educational context, per PubMed, and describes model-system and physiological research on IGF-1 and its analogs — not the laboratory research product supplied by Peptora.

1. 1Yoshida T, Delafontaine P. Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy. Cells. 2020;9(9):1970. doi:10.3390/cells9091970.
2. 2Philippou A, Barton ER. Optimizing IGF-I for skeletal muscle therapeutics. Growth Horm IGF Res. 2014;24(5):157-163. doi:10.1016/j.ghir.2014.06.003.
3. 3Hill M, Goldspink G. Expression and splicing of the insulin-like growth factor gene in rodent muscle is associated with muscle satellite (stem) cell activation following local tissue damage. J Physiol. 2003;549(Pt 2):409-418. doi:10.1113/jphysiol.2002.035832.
4. 4Velloso CP, Harridge SDR. Insulin-like growth factor-I E peptides: implications for aging skeletal muscle. Scand J Med Sci Sports. 2010;20(1):20-27. doi:10.1111/j.1600-0838.2009.00997.x.
5. 5Khamsi F, Roberge S. Differential effects of insulin-like growth factor-I and gonadotropins on the proliferative activity of two subgroups of granulosa cells (using the LR3-IGF-I analogue). Fertil Steril. 2001;75(5):997-1003. doi:10.1016/s0015-0282%2801%2901695-8.
6. 6Khamsi F, Armstrong DT. Interactions between follicle-stimulating hormone and growth factors in regulation of DNA synthesis in bovine granulosa cells (comparing long arg3-IGF-I). Biol Reprod. 1997;57(3):684-688. doi:10.1095/biolreprod57.3.684.